Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SCD | O00767 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696562 | 0.86 | PTGER4 (0.42) | PTGER4SCD | |
| SCHEMBL6288787 | 0.85 | PTGER4 (0.46) | PTGER4TP53SCDALDH1A1MMP13 | |
| SCHEMBL6696733 | 0.85 | MMP13 (0.49) | PTGER4ALDH1A1MMP13NR1H4EPHX2 | |
| SCHEMBL6813882 | 0.79 | MMP13 (0.44) | MMP13NR1H4EPHX2 | |
| SCHEMBL6703290 | 0.79 | MMP13 (0.43) | PTGER4MMP13HDAC6 | |
| SCHEMBL6289016 | 0.78 | SCD (0.43) | PTGER4SCDALDH1A1MMP13LMNA | |
| SCHEMBL6288755 | 0.77 | TP53 (0.45) | PTGER4TP53ALDH1A1MMP13EGFR | |
| SCHEMBL6701897 | 0.76 | SCD (0.52) | PTGER4TP53SCDALDH1A1MAPT | |
| SCHEMBL6699862 | 0.72 | MMP13 (0.36) | PTGER4TP53SCDMMP13 | |
| SCHEMBL6920079 | 0.70 | MMP13 (0.38) | PTGER4SCDALDH1A1MMP13HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PTGER4 1609/4885TP53 452/4885SCD 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.